Prescription drug · ANDA
Tacrolimus NDC 68462-881
Tacrolimus .3 mg/g · Ointment · Topical · Glenmark Pharmaceuticals Inc., USA
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 68462-881-35 | 68462088135 | 1 TUBE in 1 CARTON (68462-881-35) / 30 g in 1 TUBEMarketed from Aug 16, 2023 | |
| 68462-881-65 | 68462088165 | 1 TUBE in 1 CARTON (68462-881-65) / 60 g in 1 TUBEMarketed from Aug 16, 2023 | |
| 68462-881-94 | 68462088194 | 1 TUBE in 1 CARTON (68462-881-94) / 100 g in 1 TUBEMarketed from Aug 16, 2023 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Tacrolimus
- Generic name (nonproprietary)
- tacrolimus
- Active ingredients
- Tacrolimus — .3 mg/g
- Dosage form
- Ointment
- Route
- Topical
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 210393
- Marketing start
- Listing expires
- Other FDA classes
- Calcineurin Inhibitors (Mechanism)
- Identifiers
- Product ID 68462-881_15dcd504-ee3e-4f0f-a765-55e31511641eSPL ID 15dcd504-ee3e-4f0f-a765-55e31511641eSPL set ID c2d2e3a1-f346-4245-b445-6dd44e371180RxCUI 313189, 314266UNII WM0HAQ4WNMUPC 0368462534946, 0368462881941
- Pharmacologic class
- Calcineurin Inhibitor Immunosuppressant
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Topical products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N468462088135followed by a unit qualifier and the quantityPackage 68462-0881-35. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Tacrolimus ointment, both 0.03% and 0.1% for adults, and only 0.03% for children aged 2 to 15 years, is indicated as second-line therapy for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children who have failed to respond adequately to other topical prescription treatments for atopic dermatitis, or when those treatments are not advisable. Tacrolimus ointment is not indicated for children younger than 2 years of age (see boxed WARNING, WARNINGS and PRECAUTIONS: Pediatric Use).
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 210393
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Tacrolimus | Tacrolimus 1 mg/g | OintmentTopical | Glenmark Pharmaceuticals Inc., USA | 68462-534 |